Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori

Table 1 Patient profile of primary eradication therapy

	PPI group	Vonoprazan group
Average age	62.8 (18-94)	62.7 (22-89)
Gender (male:female)	902:818	170:165
PPI
Lansoprazole	1206
Omeprazole	0
Rabeprazole	62
Esomeprazole	452
Underlying disease
Chronic gastritis	1362	255
Peptic ulcer	248	55
After endoscopic therapy for early gastric cancer	107	25
Other	3	0

PPI: Proton pump inhibitor.

Table 2 Patient profile of secondary eradication therapy

	PPI group	Vonoprazan group
Average age	62.3 (19-96)	63.6 (39-89)
Gender(male:female)	182:204	28:38
PPI
Lansoprazole	266
Omeprazole	1
Rabeprazole	32
Esomeprazole	87
Underlying disease
Chronic gastritis	313	48
Peptic ulcer	44	8
After endoscopic therapy for early gastric cancer	28	10
Other	1	0

PPI: Proton pump inhibitor.

Table 3 Results of eradication therapy

	PPI group	Vonoprazan group	P value
Primary eradication therapy
ITT analysis	73.2% (1259/1720)	85.7% (287/335)	< 0.0001
PP analysis	76.4% (1259/1647)	90.3% (287/318)	< 0.0001
Secondary eradication therapy
ITT analysis	89.9% (347/386)	89.4% (59/66)	0.87
PP analysis	92.8% (347/374)	96.7% (59/61)	0.4

PPI: Proton pump inhibitor.

Table 4 Success rate and underlying disease: Primary eradication therapy

		PPI group	Vonoprazan group	P value
	ITT analysis	72.5% (988/1362)	86.7% (221/255)	< 0.0001
Chronic gastritis
	PP analysis	75.1% (988/1316)	90.6% (221/244)	< 0.0001
	ITT analysis	75.4% (187/248)	83.6% (46/55)	0.22
Peptic ulcer
	PP analysis	82.7% (187/226)	93.9% (46/49)	0.051
	ITT analysis	76.6% (82/107)	80% (20/25)	0.8
After endoscopic therapy for early gastric cancer
	PP analysis	78.1% (82/105)	80% (20/25)	1

PPI: Proton pump inhibitor.

Table 5 Success rate and underlying disease: Secondary eradication therapy

		PPI group	Vonoprazan group	P value
	ITT analysis	91.5% (292/319)	89.6% (43/48)	0.59
Chronic gastritis
	PP analysis	93.9% (292/311)	100% (43/43)	0.15
	ITT analysis	86.4% (38/44)	100% (8/8)	0.57
Peptic ulcer
	PP analysis	95.0% (38/40)	100% (8/8)	1
	ITT analysis	78.6% (22/28)	80% (8/10)	1
After endoscopic therapy for early gastric cancer
	PP analysis	78.6% (22/28)	80% (8/10)	1

PPI: Proton pump inhibitor.

Table 6 Success rate and age: Primary eradication therapy

		Younger than 50 yr	Older than 50 yr	P value
	ITT analysis	67.8% (185/273)	74.3% (1074/1446)	0.03
PPI group
	PP analysis	72.3% (185/256)	77.2% (1074/1391)	0.09
	ITT analysis	84.8% (50/59)	86.2% (238/276)	0.84
Vonoprazan group
	PP analysis	92.6% (50/54)	90.2% (238/264)	0.8

PPI: Proton pump inhibitor.